Screening for Primary Open-Angle Glaucoma in the Primary Care Setting: An Update for the US Preventive Services Task Force

Craig Fleming, MD
Evelyn P. Whitlock, MD, MPH
Tracy Beil, MS
Barbara Smit, MD, PhD
Russell P. Harris, MD, MPH

1Oregon Evidence-based Practice Center, Kaiser Permanente Center for Health Research, Portland, Ore
2Cecil G. Sheps Center for Health Service Research, The University of North Carolina at Chapel Hill, Chapel Hill, NC

ABSTRACT

PURPOSE Primary open-angle glaucoma (POAG) is a leading cause of blindness and vision-related disability. This review examines the effectiveness of screening for and treatment of early POAG in asymptomatic persons.

METHODS We identified studies of glaucoma screening and treatment from MEDLINE, the Cochrane Library, and glaucoma experts. Two reviewers abstracted relevant studies and graded articles according to US Preventive Services Task Force criteria.

RESULTS No randomized, controlled trials of population screening for POAG have been reported. Two randomized controlled trials compared the efficacy of treatment to lower intraocular pressure with no treatment for persons who have early primary open-angle glaucoma. In a Swedish trial, treatment reduced progression at 5 years from 62% without treatment to 45% with treatment (absolute risk reduction [ARR] 17%, number needed to treat 5.8, \( P = .007 \)). In a US trial of patients with early POAG and normal intraocular pressure, progression at 5 years was observed in 39% of those without treatment and 33% of those with treatment (\( P = .21 \)). The benefit of delaying progression of visual field loss on vision-related function in patients with early POAG is unclear. The principal harm of treatment is loss of visual acuity resulting from an increased risk of cataract formation.

CONCLUSIONS Treatment to lower intraocular pressure may delay progression of visual field deficits in some asymptomatic individuals with early POAG. Further studies of population screening are needed to show that early recognition and treatment of glaucoma in asymptomatic patients are effective in improving vision-specific functional outcomes and health-related quality of life.

Ann Fam Med 2005;3:167-170. DOI: 10.1370/afm.293.

INTRODUCTION

Glaucoma is an optic nerve neuropathy that leads to progressive visual field loss. Primary open-angle glaucoma (POAG), the most common type, affects an estimated 2.5 million persons in the United States, 130,000 of whom will be blind as a result.\(^1\) In most patients with POAG, however, loss of vision occurs so slowly that the average patient with POAG diagnosed at age 60 years will probably not become legally blind in either eye within his or her lifetime.\(^2\)

A definitive POAG diagnosis is based on characteristic degenerative changes in the optic disc and progressive loss of visual field sensitivity. Although most persons with POAG have intraocular pressures of greater than 21 mm Hg (the upper limit of normal), 25% to 50% have normal intraocular pressure measurements, a condition known as normal-tension glaucoma.\(^3\) Other risk factors include advanced age and family history of glaucoma.\(^4\) African descent is also an important risk factor: POAG prevalence in blacks is 4 times greater than in whites\(^5\) and is the leading cause of blindness in African Americans.
In 1996, the United States Preventive Services Task Force (USPSTF) found insufficient evidence to recommend for or against routine glaucoma screening in primary care practice. The USPSTF noted that although glaucoma treatment with medications or surgery to lower intraocular pressure had been the standard of care for many years, definitive evidence supporting the benefit of treating persons with early glaucoma and minimal visual impairment was not available. To support an updated USPSTF recommendation, we critically reviewed the literature for new evidence on the effectiveness of screening and treatment for early POAG. This article briefly summarizes the findings of the full review, which is available online at http://www.preventiveservices.ahrq.gov/.

**METHODS**

We searched MEDLINE, the Cochrane Database of Systematic Reviews, and the Cochrane Controlled Trials Register from 1994 to May 2004 to identify randomized clinical trials of screening for and treatment of primary POAG. We identified additional studies from citations in relevant articles and experts in glaucoma screening and treatment. Two reviewers abstracted relevant information and graded articles according to US Preventive Services Task Force criteria.

**RESULTS**

**Screening for POAG**

We found no randomized, controlled trials examining the effectiveness of screening and treating asymptomatic individuals for POAG in reducing or delaying progression of vision-related functional impairment. We also found no prospective studies examining the accuracy and reliability of screening for early POAG among asymptomatic patients in the primary care setting.

Although increased intraocular pressure is a risk factor for glaucoma, the effectiveness of intraocular pressure measurement as a population-screening tool for POAG appears to be limited. Many persons with POAG have normal intraocular pressure. Intraocular pressure measurements above the usual cutoff point (greater than 21 mm Hg) have an estimated sensitivity of 47% and specificity of 92% for diagnosing POAG, and intraocular pressure measurement does not appear to perform better in high-risk groups defined by age, race, sex, or family history.

Degenerative changes in the optic disc are characteristic of POAG. A dilated eye examination with direct ophthalmoscopy by an ophthalmologist has a reported sensitivity of 59% and a specificity of 73% for detecting and classifying optic disc changes associated with glaucoma. No data are available on the accuracy and reliability of direct ophthalmoscopy by primary care physicians for detecting degenerative optic disc changes associated with early POAG.

POAG also leads to characteristic patterns of visual field loss that are important to a definitive diagnosis. Perimetry assesses visual field deficits by mapping a patient’s response to visual stimuli in various locations within the visual field. The reported sensitivity and specificity of perimetry varies based on the method used and the cutoff point for defining visual field defects, as well the test used as the reference standard. The American Academy of Ophthalmology does not recommend visual field screening by perimetry as part of an eye specialist’s medical examination.

**Prevention and Treatment of Early POAG**

We found one good-quality randomized trial in patients with ocular hypertension (intraocular pressure greater than 21 mm Hg) examining the efficacy of treatment to delay onset of POAG with topical medications to lower intraocular pressure compared with no treatment. At 5 years, 4.4% of treated patients and 9.5% of untreated patients developed POAG (hazard ratio, 0.40; 95% CI, 0.27-0.59; number need to treat [NNT] 19.6). Because most patients with ocular hypertension do not develop POAG, however, whether ocular hypertension should be treated before the onset of POAG is controversial.

Several recent randomized trials have examined the efficacy of different treatment regimens for POAG. Only 2 trials compared treated patients with an untreated control group.

The Early Manifest Glaucoma Trial (EMGT) was a good-quality Swedish trial comparing the efficacy of treatment with argon laser trabeculoplasty and topical medications vs no treatment for 255 white participants with newly diagnosed, early POAG. After a median follow-up period of 6 years, a trial endpoint of POAG progression based on new visual field loss, optic disc deterioration, or both, was observed in 45% of treated patients vs 62% of the control group (absolute risk reduction [ARR] 17%; NNT 5.9; P = .007). The median time to progression was 66 months in treated patients compared with 48 months in the control group.

The EMGT study included patients with early POAG who had either normal or elevated intraocular pressure. A second controlled trial, the Collaborative Normal-Tension Glaucoma Study (CNTGS), included only patients with early POAG and normal intraocular pressure. CNTGS was a fair-quality trial comparing surgery and topical medication with no treatment in 1 eye each of 145 persons with normal tension glaucoma. At 5 years, an endpoint based on worsening of existing visual field defects or appearance of new visual field
defect was observed in 22 of 66 (33%) treated eyes and 31 of 79 (39%) untreated eyes ($P = .21$).

In the CNTGS study, 23 of 66 treated eyes (35%) developed visual acuity loss as a result of cataracts, compared with 11 of 79 eyes in the control group (14%) ($P = .0011$). In a secondary analysis, censoring eyes from further observation at the time cataracts were diagnosed resulted in an apparent reduction in glaucoma progression for treated eyes compared with control eyes ($P = .008$). This analysis, however, did not account for possible glaucoma progression that may occur after cataracts developed. Because most cataracts occurred in treated patients, censoring may have introduced a bias favoring treatment.

**Benefits of Treatment for Early POAG**

Two questions arise when interpreting the benefits of treatment for early POAG based on clinical trial outcomes. The first question is what progression means. Presently, there is no standard method for measuring visual field loss in POAG. To reduce potential harms for untreated patients, both EMGT and CNTGS used sensitive measures of visual field loss as progression endpoints. A study comparing progression endpoints used in EMGT and 2 other trials evaluating different treatment regimens found that the 3 endpoints were in agreement when classifying progression for only 23% of patients.22

The second question is how progression affects patients’ self-reported visual function or health-related quality of life. In a study of glaucoma patients with moderate-to-marked visual field loss, greater visual field loss was associated with significant decreases in self-reported visual function and general health measures.23

The absolute differences in scores between glaucoma and reference patients with cataracts were small, however, and the clinical importance of these differences was not clear. A second study found moderate correlations between decreased self-reported visual function and both visual field loss and loss of visual acuity.24

Adjustment for loss of visual acuity, however, reduced the correlation between visual field loss and decreased visual function. Other studies reportedly underway may clarify the relation between visual field loss in early POAG and vision-related function and quality of life.

**Potential Harms of Treatment for Early POAG**

The harms of treating early asymptomatic POAG are important when determining the net benefit of treatment. Based on the 6-year results of the EMGT trial, for example, only 1 in 6 patients would be expected to benefit from treatment (ARR 0.21, NNT 5.9). The other 5 patients may be exposed to potential harms of treatment without definite benefit.19

The chief harm of treatment is increased risk of cataract formation, particularly with surgery, which may lead to decreased visual acuity. In the EMGT study, treated patients received medication and/or underwent laser treatment. In the treatment group, 6 of 125 (4.8%) of patients had cataract surgery compared with 2 of 122 (1.6%) in the control group (number needed to harm [NNH] 31; $P = .148$). Visual acuity decreased at similar rates with time in both treated patients and the control group. In the CNTGS study, patients in the treatment group received either medication, laser treatment, or surgery to achieve a predetermined reduction of intraocular pressure.21 In the treatment group, 23 of 61 patients (38%) developed cataracts compared with 11 of 79 (14%) in the control group (NNH 4.8; $P = .0011$). In the treatment group, 16 of 33 (48%) surgically treated patients developed cataracts compared with 7 of 23 (30%) patients treated with medication and laser therapy ($P = .059$). No information was reported on the number of patients who underwent cataract surgery and the impact on visual acuity between treatment and control group patients.

In another trial comparing medical with surgical treatment in patients who had early POAG, surgery was associated with a significantly greater loss in visual acuity during 3.5 years of follow-up.18 Ocular symptoms, such as dryness, excessive tearing, and itching occur at similar rates in medically and surgically treated patients. Systemic medication side effects (eg, cardiovascular or mental) are uncommon.4

**DISCUSSION**

No studies examine whether population-based screening of asymptomatic persons for early open-angle glaucoma is effective in improving vision-specific function and quality of life. There is good evidence that treatment to lower intraocular pressure may delay the onset and progression of visual field deficits in some asymptomatic patients with ocular hypertension who do not have POAG (NNT 19.6) and in patients with early primary open-angle glaucoma (NNT 5.9). Treatment does not appear to benefit patients with POAG who have normal intraocular pressure. There are presently no studies that make it possible to interpret the benefit of treatment as a means of preserving vision-specific function. The potential benefits of treatment must be weighed against potential harms, particularly the increased risk for cataract formation.

Population-based glaucoma screening trials using vision-specific function and quality-of-life outcomes would be helpful to determine whether early recognition and treatment of open-angle glaucoma is beneficial. Because blacks are at greater risk for developing POAG, population-based trials will need to include a number of black participants sufficient to detect potential screening benefits.
To read or post commentaries in response to this article, see it online at http://www.annfammed.org/cgi/content/full/3/2/176.

Key words: Glaucoma, open-angle; mass screening; intraocular hypertension; evidence-based medicine; review [publication type]: AHRQ

Submitted September 16, 2004; submitted, revised, December 10, 2004; accepted January 17, 2005.

Funding support: This study was conducted by the Oregon Evidence-Based Practice Center and The Kaiser Permanente Center for Health Research under contract to the US Agency for Healthcare Research, Rockville, Maryland (contract no. 290-02-0024).

Disclaimer: The authors of this article are responsible for its contents, including any clinical or treatment recommendations. No statement in this article should be construed as an official position of the AHRQ or the US Department of Health and Human Services.

Acknowledgments: The authors thank Paula Smith, RN, BSN; Daphne Plaut, MLS; and the reviewers of the full evidence report for their contributions to this project.

Reprints: Reprints are available from the AHRQ Web site (http://www.preventiveservices.ahrq.gov). Print copies of this article, along with other USPSTF summaries of evidence and recommendation statements, are available in print from the Agency for Healthcare Research and Quality (AHRQ) Publications Clearinghouse (call 1-800-358-9295, or e-mail ahrrpubs@ahrq.gov). The recommendation is also posted on the Web site of the National Guideline Clearinghouse™ (http://www.guideline.gov).

References

1. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997;38:83-91.

2. Quigley HA, Tielsch JM, Katz J, Sommer A. Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual field damage. Am J Ophthalmol. 1996;122:355-363.

3. Quigley HA. Open-angle glaucoma. N Engl J Med. 1993;328:1097-1106.

4. American Academy of Ophthalmology. Preferred Practice Pattern. Primary Open-Angle Glaucoma. San Francisco, Calif: American Academy of Ophthalmology; 2003.

5. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA. 1991;266:369-374.

6. U.S. Preventive Services Task Force. Screening for glaucoma. In: DiGuiseppi C, Atkins D, Woolf SH, Kamerow DB, eds. Guide to Clinical Preventive Services. 2nd ed. Baltimore, Md: Williams & Wilkins; 1996:383-391.

7. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21-35.

8. Tielsch JM, Katz J, Singh K, et al. A population-based evaluation of glaucoma screening: the Baltimore Eye Survey. Am J Epidemiol. 1991;134:1102-1110.

9. Quigley HA, Katz J, Derick RJ, Gilbert D, Sommer A. An evaluation of optic disc and nerve fiber layer examinations in monitoring progression of early glaucoma damage. Ophthalmology. 1992;99:19-28.

10. Ellish NJ, Higginbotham EJ. Evaluating a visual field screening test for glaucoma: how the choice of the gold standard affects the validity of the test. Ophthalmic Epidemiol. 2001;8:297-307.

11. American Academy of Ophthalmology. Comprehensive Adult Medical Eye Evaluation. San Francisco, Calif; 2000.

12. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713; discussion 829-830.

13. Robin AL, Frick KD, Katz J, Budenz D, Tielsch JM. The ocular hypertension treatment study: intraocular pressure lowering prevents the development of glaucoma, but does that mean we should treat before the onset of disease? Arch Ophthalmol. 2004;122:375-378.

14. Jampel HD. We should treat fewer patients with elevated intraocular pressure now that we know the results of the ocular hypertension treatment study. Arch Ophthalmol. 2004;122:378-379.

15. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study. 7. Results. Glaucoma Laser Trial Research Group. Am J Ophthalmol. 1995;120:718-731.

16. The Glaucoma Laser Trial (GLT). 6. Treatment group differences in visual field changes. Glaucoma Laser Trial Research Group. Am J Ophthalmol. 1995;120:10-22.

17. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol. 2002;134:499-512.

18. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943-1953.

19. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.

20. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:487-497.

21. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:498-505.

22. Katz J, Congdon N, Friedman DS. Methodological variations in estimating apparent progressive visual field loss in clinical trials of glaucoma treatment. Arch Ophthalmol. 1999;117:1137-1142.

23. Gutierrez P, Wilson MR, Johnson C, et al. Influence of glaucomatous visual field loss on health-related quality of life. Arch Ophthalmol. 1997;115:777-784.

24. Parrish RK, 2nd, Gedde SJ, Scott IU, et al. Visual function and quality of life among patients with glaucoma. Arch Ophthalmol. 1997;115:1447-1455.